{"id":523983,"date":"2021-08-05T08:01:52","date_gmt":"2021-08-05T12:01:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-company-milestones\/"},"modified":"2021-08-05T08:01:52","modified_gmt":"2021-08-05T12:01:52","slug":"akebia-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-company-milestones","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-company-milestones\/","title":{"rendered":"Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones"},"content":{"rendered":"
\n

– Vadadustat New Drug Application (NDA) Accepted for Filing with the U.S. Food and Drug Administration (FDA)<\/h2>\n

– Vadadustat PDUFA Target Action Date of March 29, 2022<\/h2>\n

– Net Product Revenue for Auryxia\u00ae (ferric citrate) Increases to $33.0 Million, Up 7.4% from Q2’FY20<\/h2>\n

– Company to Host Conference Call Today at 9:00 a.m. ET<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CAMBRIDGE, Mass.<\/span>, Aug. 5, 2021<\/span> \/PRNewswire\/ — Akebia Therapeutics<\/a>\u00ae<\/a><\/sup>, Inc.<\/a><\/u> (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2021<\/span> and highlighted recent corporate milestones. The Company will host a conference call today, Thursday, August 5, 2021<\/span>, at 9:00 a.m. Eastern Time<\/span>.<\/p>\n

\n

\n
\n \"Akebia
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“The first half of 2021 has been marked by significant milestones that have further strengthened Akebia’s position and the potential market opportunity for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), setting the stage for an exciting and catalyst-rich year ahead for us. During the quarter, these achievements included publication of our global Phase 3 results for vadadustat in the New England Journal of Medicine<\/a><\/u><\/i> and, more recently, FDA acceptance of the vadadustat NDA for filing with a PDUFA target action date of March 29, 2022<\/span>,” stated John P. Butler<\/span>, Chief Executive Officer of Akebia. “As there are currently no approved HIF-PHIs to treat anemia due to chronic kidney disease (CKD) in the U.S., we believe vadadustat is positioned as a potential first-in-class product with a broader opportunity in the dialysis market than originally anticipated. With vadadustat’s PDUFA date set for March, we are highly focused on pre-launch activities to ensure that we are well positioned for a successful U.S. launch in 2022, and are excited to be one step closer to having a novel, oral therapeutic available for people living with this disease, subject to regulatory approval.”<\/p>\n

\n Steven K. Burke<\/span>, M.D., Senior Vice President, Research & Development and Chief Medical Officer of\u202fAkebia stated, “We remain confident in the clarity and quality of our data, and continue to be encouraged by the safety profile of vadadustat demonstrated in our global Phase 3 program for the treatment of anemia due to CKD. As seen in the recent New England Journal of Medicine<\/a><\/u><\/i> publications of our global Phase 3 results, the data showed no significant safety signals on adverse events, including thromboembolic events, seizures and infections. More specifically, the data showed that these events were very similar for vadadustat as compared to darbepoetin alfa.”<\/p>\n

Akebia is also working in close collaboration with its partner, Otsuka Pharmaceutical Co. Ltd., to prepare a Marketing Authorization Application for vadadustat for submission to the European Medicines Agency, expected this year. <\/p>\n

\n Recent Business Highlights: <\/b>\n <\/p>\n